Prostate Cancer

A feasibility study of the repurposing of prazosin to improve treatment outcomes in men receiving radiotherapy for prostate cancer (MiniRaP-00).

A feasibility study of the repurposing of prazosin to improve treatment outcomes in men receiving radiotherapy for prostate cancer (MiniRaP-00).

Trial overview


Prostate cancer 

Study details

The purpose of this study is determine whether it is possible to use a drug called prazosin when men are undergoing radiotherapy for the treatment of prostate cancer.

All participants in this study will be asked to take prazosin two times day starting the week before and until the completion of their radiotherapy treatment for prostate cancer. The dose of medication provided will increase week by week until the final week.

Participants will be monitored throughout the treatment period to determine if they are willing to take the medication alongside their radiation, and followed for 9 months for any side effects.

It is hoped that this study will help determine if it is possible to use prazosin while participants are completing radiotherapy, and help guide the development of a large scale clinical trial which will be used to investigate the efficacy of prazosin combined with radiotherapy.

Eligibility criteria

Key inclusion criteria:

Histologically confirmed adenocarcinoma of the prostate

  • Age greater or equal to 18 years
  • Normal bone marrow function: Hb greater than or equal to 100 g/L, WCC greater than or equal to 4.0 x 109 cells/L, Platelets greater than or equal to 100 x 10^9 cells/L
  • Normal liver function: ALT <2x ULN, Bilirubin <1.5 x ULN or normal conjugated bilirubin
  • Normal renal function: Calculated creatinine clearance >40 mL/min using Cockcroft-Gault formula
  • ECOG performance status of 0-1
  • Participants capable of childbearing only if using adequate contraception
  • Willingness to comply with all study procedures including IP administration protocol and required testing
  • Signed, written and informed consent
  • Participants are available for follow up

Key exclusion criteria:

  • Evidence of >5 metastatic sites: Suspected or confirmed by appropriate imaging.
  • Under the age of 18 years
  • Presence of any medical, psychological or social condition that may hinder compliance
  • Use of hormonal therapy more than 30 days prior to commencement of prazosin, other than ADT prescribed for the treatment of PCa
  • History of any other previous malignancy within 5 years of the commencement of prazosin, other than successfully treated squamous cell or basal cell carcinoma of the skin
  • Previous bilateral orchidectomy
  • Has received prior brachytherapy or radiotherapy for PCa to the same
Further information

Please click here for more information

Tugun (Oncology) :::
Southport (Oncology) :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.